UK markets close in 8 hours 29 minutes
  • FTSE 100

    7,494.13
    0.00 (0.00%)
     
  • FTSE 250

    22,263.24
    0.00 (0.00%)
     
  • AIM

    1,132.08
    0.00 (0.00%)
     
  • GBP/EUR

    1.1958
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.3542
    -0.0004 (-0.03%)
     
  • BTC-GBP

    25,797.51
    -609.32 (-2.31%)
     
  • CMC Crypto 200

    803.56
    +560.88 (+231.12%)
     
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • DOW

    34,265.37
    -450.03 (-1.30%)
     
  • CRUDE OIL

    85.68
    +0.54 (+0.63%)
     
  • GOLD FUTURES

    1,837.30
    +5.50 (+0.30%)
     
  • NIKKEI 225

    27,588.37
    +66.11 (+0.24%)
     
  • HANG SENG

    24,648.58
    -316.97 (-1.27%)
     
  • DAX

    15,603.88
    -308.42 (-1.94%)
     
  • CAC 40

    7,068.59
    -125.57 (-1.75%)
     

Moderna improves forecast for 2022 sales from COVID-19 vaccine

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: People pose with syringe with needle in front of displayed Moderna logo
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • MRNA

(Reuters) -Moderna Inc said on Monday it expected to record sales of about $18.5 billion in 2022 from contracts for its COVID-19 vaccine, and about $3.5 billion from potential additional purchases including booster candidates updated for variants.

The company in November said its sales could be in the range of $17 billion to $22 billion in 2022.

Moderna said it was in active discussions for additional COVID-19 vaccine contracts this year.

The company also said it was developing a booster vaccine candidate, called mRNA-1273.529, that targets the fast-spreading Omicron variant and expects it to advance into clinical trials in early 2022.

Booster doses of the company's current COVID-19 vaccine, mRNA-1273, increased neutralizing antibody levels against Omicron at both 50 microgram and 100 microgram dose levels, the drugmaker said.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting